Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Blood Cancer Discovery · Published 2026-04-14 · DOI 10.1158/2643-3230.bcd-25-0477

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1158/2643-3230.bcd-25-0477

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Improving Knowledge and Care of Patients with AML: The Need to Get Out of Our Comfort Zone · Blood Cancer Discovery · 2026 · Same journal
• MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1 -Mutant Leukemia · Blood Cancer Discovery · 2026 · Same journal
• Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry · Blood Cancer Discovery · 2026 · Same journal
• LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models · Blood Cancer Discovery · 2026 · Same journal
• Rewiring the Leukemic Genome: 3D Chromatin Architecture in B-cell Acute Lymphoblastic Leukemia · Blood Cancer Discovery · 2026 · Same journal
• The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells · Blood Cancer Discovery · 2026 · Same journal
• Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies · Blood Cancer Discovery · 2026 · Same journal
• Highlighted Research Articles · Blood Cancer Discovery · 2026 · Same journal
• Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma · Blood Cancer Discovery · 2026 · Same journal
• A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma · Blood Cancer Discovery · 2026 · Same journal